Compare Eli Lilly And Co (LLY) vs IAC/Interactivecorp (PPLI) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

PPLI trades at $44.71, up 0.4% today, with a bullish technical signal from moving averages and oversold short-term RSI. Recent quarters show earnings misses, but revenue stabilized near $2.4B in 2025. The stock trades below book value (P/B 0.73) and carries a consensus price target of $55.40. News highlights potential MGM acquisition talks and Q2 2026 earnings call scheduled for August 4th.

Outlook is mixed: strong analyst buy ratings (64%) and undervaluation signals support upside, but persistent net losses and volatile cash flows pose risks. Investors should weigh the discount to NAV against execution challenges in achieving profitability.